Effect of levosimendan on ventricular remodelling in patients with left ventricular systolic dysfunction: a meta-analysis.
Left ventricular systolic dysfunction
Levosimendan
Meta-analysis
Safety
Ventricular remodelling
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
28 Feb 2024
28 Feb 2024
Historique:
revised:
10
01
2024
received:
17
11
2023
accepted:
18
01
2024
medline:
29
2
2024
pubmed:
29
2
2024
entrez:
29
2
2024
Statut:
aheadofprint
Résumé
Heart failure is the final stage of several cardiovascular diseases, and the key to effectively treating heart failure is to reverse or delay ventricular remodelling. Levosimendan is a novel inotropic and vasodilator agent used in heart failure, whereas the impact of levosimendan on ventricular remodelling is still unclear. This study aims to investigate the impact of levosimendan on ventricular remodelling in patients with left ventricular systolic dysfunction. Electronic databases were searched to identify eligible studies. A total of 66 randomized controlled trials involving 7968 patients were included. Meta-analysis results showed that levosimendan increased left ventricular ejection fraction [mean difference (MD) = 3.62, 95% confidence interval (CI) (2.88, 4.35), P < 0.00001] and stroke volume [MD = 6.59, 95% CI (3.22, 9.96), P = 0.0001] and significantly reduced left ventricular end-systolic volume [standard mean difference (SMD) = -0.52, 95% CI (-0.67, -0.37), P < 0.00001], left ventricular end-diastolic volume index [SMD = -1.24, 95% CI (-1.61, -0.86), P < 0.00001], and left ventricular end-systolic volume index [SMD = -1.06, 95% CI (-1.43, -0.70), P < 0.00001]. In terms of biomarkers, levosimendan significantly reduced the level of brain natriuretic peptide [SMD = -1.08, 95% CI (-1.60, -0.56), P < 0.0001], N-terminal pro-brain natriuretic peptide [SMD = -0.99, 95% CI (-1.41, -0.56), P < 0.00001], and interleukin-6 [SMD = -0.61, 95% CI (-0.86, -0.35), P < 0.00001]. Meanwhile, levosimendan may increase the incidence of hypotension [risk ratio (RR) = 1.24, 95% CI (1.12, 1.39), P < 0.0001], hypokalaemia [RR = 1.57, 95% CI (1.08, 2.28), P = 0.02], headache [RR = 1.89, 95% CI (1.50, 2.39), P < 0.00001], atrial fibrillation [RR = 1.31, 95% CI (1.12, 1.52), P = 0.0005], and premature ventricular complexes [RR = 1.86, 95% CI (1.27, 2.72), P = 0.001]. In addition, levosimendan reduced all-cause mortality [RR = 0.83, 95% CI (0.74, 0.94), P = 0.002]. In conclusion, our study found that levosimendan might reverse ventricular remodelling when applied in patients with left ventricular systolic dysfunction, especially in patients undergoing cardiac surgery, decompensated heart failure, and septic shock.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Natural Science Foundation of China
ID : 81900332
Organisme : National Natural Science Foundation of China
ID : 82070392
Organisme : Cardiovascular Multidisciplinary Integrated Research Fund
ID : z-2016-23-2101-10
Organisme : Chinese Cardiovascular Association-Access Fund
ID : 2021-CCA-ACCESS-142
Organisme : Taishan Scholars
ID : tsqn202103146
Informations de copyright
© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-2200. doi:10.1093/eurheartj/ehw128
Bragazzi NL, Zhong W, Shu J, Abu Much A, Lotan D, Grupper A, et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur J Prev Cardiol 2021;28:1682-1690. doi:10.1093/eurjpc/zwaa147
Cavefors O, Holmqvist J, Bech-Hanssen O, Einarsson F, Norberg E, Lundin S, et al. Regional left ventricular systolic dysfunction associated with critical illness: Incidence and effect on outcome. ESC heart failure 2021;8:5415-5423. doi:10.1002/ehf2.13633
Petersen JW, Felker GM. Inotropes in the management of acute heart failure. Crit Care Med 2008;36:S106-S111. doi:10.1097/01.CCM.0000296273.72952.39
Kamisah Y, Che Hassan HH. Therapeutic use and molecular aspects of ivabradine in cardiac remodeling: A review. Int J Mol Sci 2023;24:2801. doi:10.3390/ijms24032801
Martins D, Garcia LR, Queiroz DAR, Lazzarin T, Tonon CR, Balin PDS, et al. Oxidative stress as a therapeutic target of cardiac remodeling. Antioxidants (Basel) 2022;11:2371. doi:10.3390/antiox11122371
Mann DL. Cardiac remodeling as therapeutic target: Treating heart failure with cardiac support devices. Heart Fail Rev 2005;10:93-94. doi:10.1007/s10741-005-4635-z
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145: doi:10.1161/CIR.0000000000001063
Li X, Qi Y, Li Y, Zhang S, Guo S, Chu S, et al. Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction: A meta-analysis of randomized controlled trials. Circ Heart Fail 2013;6:156-165. doi:10.1161/CIRCHEARTFAILURE.112.000074
Aimo A, Vergaro G, González A, Barison A, Lupón J, Delgado V, et al. Cardiac remodelling-Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2022;24:944-958. doi:10.1002/ejhf.2522
Konstam MA, Kronenberg MW, Rousseau MF, Udelson JE, Melin J, Stewart D, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators. Circulation 1993;88:2277-2283. doi:10.1161/01.CIR.88.5.2277
St John Sutton M, Pfeffer MA, Moye L, Plappert T, Rouleau JL, Lamas G, et al. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: Baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation 1997;96:3294-3299. doi:10.1161/01.CIR.96.10.3294
Consensus Trial Study Group*. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435. doi:10.1056/NEJM198706043162301
Colucci WS, Kolias TJ, Adams KF, Armstrong WF, Ghali JK, Gottlieb SS, et al. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: The REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation 2007;116:49-56. doi:10.1161/CIRCULATIONAHA.106.666016
Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997;29:1060-1066. doi:10.1016/S0735-1097(97)00012-0
Palazzuoli A, Bruni F, Puccetti L, Pastorelli M, Angori P, Pasqui AL, et al. Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure. Eur J Heart Fail 2002;4:765-770. doi:10.1016/S1388-9842(02)00114-9
Cohn JN. Myocardial structural effects of aldosterone receptor antagonism in heart failure. J Am Coll Cardiol 2007;50:597-599. doi:10.1016/j.jacc.2007.04.063
Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003;107:2559-2565. doi:10.1161/01.CIR.0000068340.96506.0F
Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001;37:1228-1233. doi:10.1016/S0735-1097(01)01116-0
Januzzi JL, Omar AMS, Liu Y, Murphy S, Butler J, Felker GM, et al. Association between sacubitril/valsartan initiation and mitral regurgitation severity in heart failure with reduced ejection fraction: The PROVE-HF study. Circulation 2022;146:1638-1640. doi:10.1161/CIRCULATIONAHA.122.061693
Myhre PL, Claggett BL, Shah AM, Prescott MF, Ward JH, Fang JC, et al. Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: The EVALUATE-HF trial. Eur J Heart Fail 2022;24:1200-1208. doi:10.1002/ejhf.2541
Jensen J, Omar M, Kistorp C, Tuxen C, Gustafsson I, Køber L, et al. Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): A prespecified substudy of a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2021;9:106-116. doi:10.1016/S2213-8587(20)30382-X
Lee MMY, Gillis KA, Brooksbank KJM, Allwood-Spiers S, Hall Barrientos P, Wetherall K, et al. Effect of empagliflozin on kidney biochemical and imaging outcomes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation 2022;146:364-367. doi:10.1161/CIRCULATIONAHA.122.059851
Firth BG, Dunnmon PM. The prevention of congestive heart failure: Left ventricular dilation and its management. Am J Med Sci 1990;299:276-290. doi:10.1097/00000441-199004000-00010
Francis GS, Bartos JA, Adatya S. Inotropes. J Am Coll Cardiol 2014;63:2069-2078. doi:10.1016/j.jacc.2014.01.016
Mebazaa A, Erhardt L. Levosimendan: A new dual-action drug in the treatment of acute heart failure. Int J Clin Pract 2003;57:410-416.
Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468-1475. doi:10.1056/NEJM199111213252103
Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Lindén IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995;27:1859-1866. doi:10.1016/0022-2828(95)90009-8
Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 2006;113:305-315. doi:10.1161/circulationaha.105.542407
Papp Z, Édes I, Fruhwald S, De Hert SG, Salmenperä M, Leppikangas H, et al. Levosimendan: Molecular mechanisms and clinical implications: Consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol 2012;159:82-87. doi:10.1016/j.ijcard.2011.07.022
Pollesello P, Papp Z. The cardioprotective effects of levosimendan: Preclinical and clinical evidence. J Cardiovasc Pharmacol 2007;50:257-263. doi:10.1097/FJC.0b013e3180986230
Yildiz O. Vasodilating mechanisms of levosimendan: Involvement of K+ channels. J Pharmacol Sci 2007;104:1-5. doi:10.1254/jphs.cp0060010
Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet (London, England) 2002;360:196-202. doi:10.1016/s0140-6736(02)09455-2
Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1903-1912. doi:10.1016/s0735-1097(00)00961-x
Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000;102:2222-2227. doi:10.1161/01.cir.102.18.2222
Grześk G, Wołowiec Ł, Rogowicz D, Gilewski W, Kowalkowska M, Banach J, et al. The importance of pharmacokinetics, pharmacodynamic and repetitive use of levosimendan. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 2022;153:113391. doi:10.1016/j.biopha.2022.113391
Belletti A, Castro ML, Silvetti S, Greco T, Biondi-Zoccai G, Pasin L, et al. The effect of inotropes and vasopressors on mortality: A meta-analysis of randomized clinical trials. Br J Anaesth 2015;115:656-675. doi:10.1093/bja/aev284
Comín-Colet J, Manito N, Segovia-Cubero J, Delgado J, García Pinilla JM, Almenar L, et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: The LION-HEART multicentre randomised trial. Eur J Heart Fail 2018;20:1128-1136. doi:10.1002/ejhf.1145
Ikonomidis I, Parissis JT, Paraskevaidis I, Kourea K, Bistola V, Lekakis J, et al. Effects of levosimendan on coronary artery flow and cardiac performance in patients with advanced heart failure. Eur J Heart Fail 2007;9:1172-1177. doi:10.1016/j.ejheart.2007.10.002
Morelli A, De Castro S, Teboul JL, Singer M, Rocco M, Conti G, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005;31:638-644. doi:10.1007/s00134-005-2619-z
Louhelainen M, Vahtola E, Forsten H, Merasto S, Kytö V, Finckenberg P, et al. Oral levosimendan prevents postinfarct heart failure and cardiac remodeling in diabetic Goto-Kakizaki rats. J Hypertens 2009;27:2094-2107. doi:10.1097/HJH.0b013e32832f0ce4
Louhelainen M, Vahtola E, Kaheinen P, Leskinen H, Merasto S, Kytö V, et al. Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats. Br J Pharmacol 2007;150:851-861. doi:10.1038/sj.bjp.0707157
Tarkia M, Stark C, Haavisto M, Kentala R, Vähäsilta T, Savunen T, et al. Effect of levosimendan therapy on myocardial infarct size and left ventricular function after acute coronary occlusion. Heart (British Cardiac Society) 2016;102:465-471. doi:10.1136/heartjnl-2015-308137
Vahtola E, Storvik M, Louhelainen M, Merasto S, Lakkisto P, Lakkisto J, et al. Effects of levosimendan on cardiac gene expression profile and post-infarct cardiac remodelling in diabetic Goto-Kakizaki rats. Basic Clin Pharmacol Toxicol 2011;109:387-397. doi:10.1111/j.1742-7843.2011.00743.x
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. J Clin Epidemiol 2009;62:e1-e34. doi:10.1016/j.jclinepi.2009.06.006
Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006;98:102-106. doi:10.1016/j.amjcard.2006.01.068
Al-Shawaf E, Ayed A, Vislocky I, Radomir B, Dehrab N, Tarazi R. Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery. J Cardiothorac Vasc Anesth 2006;20:353-357. doi:10.1053/j.jvca.2006.02.012
Alvarez J, Bouzada M, Fernández AL, Caruezo V, Taboada M, Rodríguez J, et al. Hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery. Revista espanola de cardiologia 2006;59:338-345. doi:10.1016/S1885-5857(06)60770-6
Anastasiadis K, Antonitsis P, Vranis K, Kleontas A, Asteriou C, Grosomanidis V, et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: A randomized pilot study. Interact Cardiovasc Thorac Surg 2016;23:740-747. doi:10.1093/icvts/ivw213
Avgeropoulou C, Andreadou I, Markantonis-Kyroudis S, Demopoulou M, Missovoulos P, Androulakis A, et al. The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. Eur J Heart Fail 2005;7:882-887. doi:10.1016/j.ejheart.2005.02.002
Berger R, Moertl D, Huelsmann M, Bojic A, Ahmadi R, Heissenberger I, et al. Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. Eur J Heart Fail 2007;9:202-208. doi:10.1016/j.ejheart.2006.06.001
Bergh CH, Andersson B, Dahlström U, Forfang K, Kivikko M, Sarapohja T, et al. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail 2010;12:404-410. doi:10.1093/eurjhf/hfq032
Biteker M, Duran NE, Kaya H, Gündüz S, Tanboğa H, Gökdeniz T, et al. Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial. Clinical research in cardiology : official journal of the German Cardiac Society 2011;100:571-577. doi:10.1007/s00392-010-0279-7
Bonios MJ, Terrovitis JV, Drakos SG, Katsaros F, Pantsios C, Nanas SN, et al. Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure. Int J Cardiol 2012;159:225-229. doi:10.1016/j.ijcard.2011.03.013
Cui XR, Yang XH, Li RB, Wang D, Jia M, Bai L, et al. Short-term efficacy and safety of levosimendan in patients with chronic systolic heart failure. Cardiovasc J Afr 2020;31:196-200. doi:10.5830/cvja-2020-008
Duman D, Palit F, Simsek E, Bilgehan K, Sacide A. Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure. Can J Cardiol 2009;25:e353-e356. doi:10.1016/s0828-282x(09)70721-4
Duygu H, Nalbantgil S, Ozerkan F, Zoghi M, Akilli A, Erturk U, et al. Effects of levosimendan on left atrial functions in patients with ischemic heart failure. Clin Cardiol 2008;31:607-613. doi:10.1002/clc.20332
Duygu H, Nalbantgil S, Zoghi M, Ozerkan F, Yildiz A, Akilli A, et al. Comparison of ischemic side effects of levosimendan and dobutamine with integrated backscatter analysis. Clin Cardiol 2009;32:187-192. doi:10.1002/clc.20313
Duygu H, Ozerkan F, Zoghi M, Nalbantgil S, Yildiz A, Akilli A, et al. Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure. Int J Clin Pract 2008;62:228-233. doi:10.1111/j.1742-1241.2007.01510.x
Duygu H, Turk U, Ozdogan O, Akyuz S, Kirilmaz B, Alioglu E, et al. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol. Cardiovasc Ther 2008;26:182-188. doi:10.1111/j.1755-5922.2008.00050.x
Eriksson HI, Jalonen JR, Heikkinen LO, Kivikko M, Laine M, Leino KA, et al. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Ann Thorac Surg 2009;87:448-454. doi:10.1016/j.athoracsur.2008.10.029
Fang M, Dong S. Effects of levosimendan on hemodynamics and cardiac function in patients with septic shock. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2014;26:692-696. doi:10.3760/cma.j.issn.2095-4352.2014.10.002
Flevari P, Parissis JT, Leftheriotis D, Panou F, Kourea K, Kremastinos DT. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol 2006;98:1641-1645. doi:10.1016/j.amjcard.2006.07.043
García-González MJ, Aldea Perona A, Lara Padron A, Morales Rull JL, Martínez-Sellés M, de Mora MM, et al. Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: The LAICA study. ESC Heart Failure 2021;8:4820-4831. doi:10.1002/ehf2.13670
García-González MJ, Domínguez-Rodríguez A, Ferrer-Hita JJ, Abreu-González P, Muñoz MB. Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail 2006;8:723-728. doi:10.1016/j.ejheart.2006.01.007
Guo Y, Zhang D, Ge Y, Wu R, Xie Q, Li W. Effect of levosimendan on ventricular systolic synchronicity in chronic heart failure. Journal of Clinical Cardiology 2013;29:254-256.
Hu X, Xu Q. Application of levosimendan in severe patients after cardiac surgery. Chinese Journal of Clinical Pharmacology and Therapeutics 2020;25:1027-1032. doi:10.12092/j.issn.1009-2501.2020.09.010
Huang Y, Li Y, Wei Y, Liu B, Xu W. Effectiveness of levosimendan versus dobutamine for the patients with severe valvular disease in perioperative period: A randomized controlled trial. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2015;22:423-427.
Husebye T, Eritsland J, Müller C, Sandvik L, Arnesen H, Seljeflot I, et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: A randomized, placebo-controlled study. Eur J Heart Fail 2013;15:565-572. doi:10.1093/eurjhf/hfs215
Jia Z, Guo M, Zhang L, Zhang Y, Liang H, Tian S, et al. Efficacy of levosimendan vs. milrinone in decompensated heart failure patients. Chinese Journal of Emergency Medicine 2014;23:740-745.
Jia Z, Guo M, Zhang LY, Zhang YQ, Liang HQ, Song Y. Levosimendan and nesiritide as a combination therapy in patients with acute heart failure. Am J Med Sci 2015;349:398-405. doi:10.1097/maj.0000000000000461
Jia Z, Guo M, Zhang YQ, Liang HQ, Zhang LY, Song Y. Efficacy of intravenous levosimendan in patients with heart failure complicated by acute myocardial infarction. Cardiology 2014;128:195-201. doi:10.1159/000357864
John B, Babu M, Shaji S, Abraham S, Abdullakutty J. Clinical outcomes of levosimendan versus dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function. Indian Heart J 2021;73:372-375. doi:10.1016/j.ihj.2021.02.010
Kasikcioglu HA, Unal S, Tartan Z, Uyarel H, Okmen E, Kasikcioglu E, et al. Effects of levosimendan on left ventricular functional remodelling and exercise intolerance: A tissue Doppler study. J Int Med Res 2005;33:397-405. doi:10.1177/147323000503300405
Kasikcioglu HA, Uyarel H, Tartan Z, Kasikcioglu E, Ozturk R, Cam N. Do calcium sensitizers affect right ventricular functions in patients with chronic heart failure? Int J Cardiol 2007;118:246-248. doi:10.1016/j.ijcard.2006.06.054
Li Z, Lai X, Shi Z, Bao Y. Combination of dobutamine and levosimendan in patients with severe heart failure. Chinese Journal of New Drugs and Clinical Remedies 2014;33:534-538.
Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail 2007;9:75-82. doi:10.1016/j.ejheart.2006.04.012
Malfatto G, Della Rosa F, Villani A, Rella V, Branzi G, Facchini M, et al. Intermittent levosimendan infusions in advanced heart failure: Favourable effects on left ventricular function, neurohormonal balance, and one-year survival. J Cardiovasc Pharmacol 2012;60:450-455. doi:10.1097/FJC.0b013e31826b86aa
Mavrogeni S, Giamouzis G, Papadopoulou E, Thomopoulou S, Dritsas A, Athanasopoulos G, et al. A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure. J Card Fail 2007;13:556-559. doi:10.1016/j.cardfail.2007.04.004
Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE randomized trial. JAMA 2007;297:1883-1891. doi:10.1001/jama.297.17.1883
Mehta RH, Leimberger JD, van Diepen S, Meza J, Wang A, Jankowich R, et al. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N Engl J Med 2017;376:2032-2042. doi:10.1056/NEJMoa1616218
Meng JB, Hu MH, Lai ZZ, Ji CL, Xu XJ, Zhang G, et al. Levosimendan versus dobutamine in myocardial injury patients with septic shock: A randomized controlled trial. Med Sci Monit Int Med J Exp Clin Res 2016;22:1486-1496. doi:10.12659/msm.898457
Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction-A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002;23:1422-1432. doi:10.1053/euhj.2001.3158
Mushtaq S, Andreini D, Farina S, Salvioni E, Pontone G, Sciomer S, et al. Levosimendan improves exercise performance in patients with advanced chronic heart failure. ESC Heart Failure 2015;2:133-141. doi:10.1002/ehf2.12047
Niu Z, Sun L, Lin M, Sun L, Sheng W, Hou W, et al. Clinical effect of levosimendan in patients with left ventricular systolic dysfunction under off-pump coronary artery bypass grafting. Chin J Clin Pharmacol Ther 2013;18:1160-1163.
Oner E, Erturk M, Birant A, Kurtar Mansıroglu A, Akturk IF, Karakurt H, et al. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure. Cardiol J 2015;22:87-93. doi:10.5603/CJ.a2014.0044
Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Failure 2013;1:103-111. doi:10.1016/j.jchf.2012.12.004
Parissis JT, Adamopoulos S, Antoniades C, Kostakis G, Rigas A, Kyrzopoulos S, et al. Effects of levosimendan on circulating proinflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. American Journal of Cardiology 2004;93:1309-1312. doi:10.1016/j.amjcard.2004.01.073
Parissis JT, Adamopoulos S, Farmakis D, Filippatos G, Paraskevaidis I, Panou F, et al. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart (British Cardiac Society) 2006;92:1768-1772. doi:10.1136/hrt.2006.079707
Parissis JT, Andreadou I, Markantonis SL, Bistola V, Louka A, Pyriochou A, et al. Effects of levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure. Atherosclerosis 2007;195:e210-e215. doi:10.1016/j.atherosclerosis.2007.07.011
Parissis JT, Karavidas A, Bistola V, Arapi S, Paraskevaidis IA, Farmakis D, et al. Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure. Atherosclerosis 2008;197:278-282. doi:10.1016/j.atherosclerosis.2007.04.023
Parissis JT, Panou F, Farmakis D, Adamopoulos S, Filippatos G, Paraskevaidis I, et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 2005;96:423-426. doi:10.1016/j.amjcard.2005.03.092
Parissis JT, Paraskevaidis I, Bistola V, Farmakis D, Panou F, Kourea K, et al. Effects of levosimendan on right ventricular function in patients with advanced heart failure. Am J Cardiol 2006;98:1489-1492. doi:10.1016/j.amjcard.2006.06.052
Shi D, Zhang J, Cui L, Liu X, Mi B, Cui J. Effect of levosimendan on ventricular systolic synchronicity in patients with chronic systolic heart failure. Wuhan Daxue Xuebao (Yixue Ban) 2014;35:922-924.
Su L-j, Bai X-j, Wang B, Yang G, Zhang H-s, Qi G-x. Efficacy of levosimendan in congestive heart failure. Journal of China Medical University 2008;37:263-266.
Wang YB, Hao GZ, Jiang YF, Fu XH, Fan WZ, Miao Q, et al. Effects of levosimendan on right ventricular function in patients with acute decompensated heart failure. Acta Cardiologica Sinica 2019;35:585-591. doi:10.6515/acs.201911_35(6).20190327a
Wu X, Wu J, Yan X, Zhang Y. Enhancement of myocardial function and reduction of injury with levosimendan after percutaneous coronary intervention for acute myocardial infarction: A pilot study. Cardiology 2014;128:202-208. doi:10.1159/000360933
Xu CX, Li L, Gong SJ, Yu YH, Yan J. The effects of levosimendan on the cardiac function and prognosis in elderly patients with septic shock and myocardial contractility impairment. Zhonghua Nei Ke Za Zhi 2018;57:423-428. doi:10.3760/cma.j.issn.0578-1426.2018.06.006
Yao R, Sun T, Du Y, Li Y, Zhang Y, Li L. A clinical comparative study of levosimendan on patients with acutely heart failure. Chinese J Emerg Med 2015;24:893-896.
Yontar OC, Yilmaz MB, Yalta K, Erdem A, Tandogan I. Acute effects of levosimendan and dobutamine on QRS duration in patients with heart failure. Arq Bras Cardiol 2010;95:738-742. doi:10.1590/s0066-782x2010005000143
Yu F, Fu Y, Liu H, Li X, Fan J, Liao B, et al. Influence of levosimendan on severe valvular disease patients with atrial fibrillation undergoing cardiac surgery: A randomized controlled trial. Chin J Clin Thoracic Cardiovasc Surg 2015;22:288-291.
Yu S, Zhang J. Effects of levosimendan preconditioning on left ventricular remodeling after myocardial reperfusion in acute myocardial infarction patients receiving percutaneous coronary intervention. Heart Surg Forum 2022;25:E001-e007. doi:10.1532/hsf.4267
Yuan F, Liu H, Zhang M, Fang W. Comparison of clinical outcomes between levosimendan and recombinant B-type natriuretic peptide for heart and renal function in acute decompensated heart failure patients. Shanghai Med J 2013;36:915-919.
Zangrillo A, Lomivorotov VV, Pisano A, Calabrò MG, Belletti A, Brazzi L, et al. Long-term outcome of perioperative low cardiac output syndrome in cardiac surgery: 1-year results of a multicenter randomized trial. J Crit Care 2020;58:89-95. doi:10.1016/j.jcrc.2020.04.005
Zhang D, Yao Y, Qian J, Huang J. Levosimendan improves clinical outcomes of refractory heart failure in elderly Chinese patients. Med Sci Monitor Int Med J Exp Clinical Res 2015;21:2439-2445. doi:10.12659/msm.893580
Zhang L, Li H. The effect of levosimendan on cardiac function of patients with refractory heart failure. Chin J Integ Trad Western Med Intens Crit Care 2019;26:306-308.
Zhang YH, Zhang J, Qing EM, Li H, Sun YX, Zhang L, et al. Comparison on efficacy and safety between domestic levosimendan versus dobutamine for patients with acute decompensated heart failure. Zhonghua Xin Xue Guan Bing Za Zhi 2012;40:153-156.
Pan L, Pan X, Xu J, Mao M. Clinical trial of levosimendan injection in the treatment of patients with tuberculous pericarditis who underwent pericardial strip. Chin J Clin Pharmacol 2018;34:399-402.
Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-Concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. On behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000;35:569-582. doi:10.1016/S0735-1097(99)00630-0
Schirone L, Forte M, Palmerio S, Yee D, Nocella C, Angelini F, et al. A review of the molecular mechanisms underlying the development and progression of cardiac remodeling. Oxid Med Cell Longev 2017;2017:3920195. doi:10.1155/2017/3920195
Long Y-X, Cui D-Y, Kuang X, Hu S, Hu Y, Liu Z-Z. Effect of levosimendan on ventricular systolic and diastolic functions in heart failure patients: A meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol 2021;77:805-813. doi:10.1097/FJC.0000000000001010
Hu Y, Wei Z, Zhang C, Lu C, Zeng Z. The effect of levosimendan on right ventricular function in patients with heart dysfunction: A systematic review and meta-analysis. Sci Rep 2021;11:24097. doi:10.1038/s41598-021-03317-5
Cui D, Liao Y, Li G, Chen Y. Levosimendan can improve the level of B-type natriuretic peptide and the left ventricular ejection fraction of patients with advanced heart failure: A meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs 2021;21:73-81. doi:10.1007/s40256-020-00416-y
Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310. doi:10.1056/NEJM199108013250502
Azevedo PS, Polegato BF, Minicucci MF, Paiva SAR, Zornoff LAM. Cardiac remodeling: Concepts, clinical impact, pathophysiological mechanisms and pharmacologic treatment. Arq Bras Cardiol 2016;106:62-69. doi:10.5935/abc.20160005
Michels da Silva D, Langer H, Graf T. Inflammatory and molecular pathways in heart failure-Ischemia, HFpEF and transthyretin cardiac amyloidosis. Int J Mol Sci 2019;20:2322. doi:10.3390/ijms20092322
González A, Richards AM, de Boer RA, Thum T, Arfsten H, Hülsmann M, et al. Cardiac remodelling-Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2022;24:927-943. doi:10.1002/ejhf.2493
Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: Comparison with Doppler velocity recordings. Circulation 2002;105:595-601. doi:10.1161/hc0502.103010
Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JEL, Shah T, Sofat R, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: A mendelian randomisation analysis. Lancet (London, England) 2012;379:1214-1224. doi:10.1016/S0140-6736(12)60110-X
Fonseca FA, Izar MC. Role of inflammation in cardiac remodeling after acute myocardial infarction. Front Physiol 2022;13:927163. doi:10.3389/fphys.2022.927163
Huang X, Lei S, Zhu M-f, Jiang R-l, Huang L-q, Xia G-l, et al. Levosimendan versus dobutamine in critically ill patients: A meta-analysis of randomized controlled trials. J Zhejiang Univ Sci B 2013;14:400-415. doi:10.1631/jzus.B1200290
Pollesello P, Parissis J, Kivikko M, Harjola VP. Levosimendan meta-analyses: Is there a pattern in the effect on mortality? Int J Cardiol 2016;209:77-83. doi:10.1016/j.ijcard.2016.02.014
Landoni G, Biondi-Zoccai G, Greco M, Greco T, Bignami E, Morelli A, et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med 2012;40:634-646. doi:10.1097/CCM.0b013e318232962a
Jaguszewski MJ, Gasecka A, Targonski R, Filipiak KJ, Szarpak L. Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis. Cardiol J 2021;28:492-493. doi:10.5603/CJ.a2021.0037
Tena MÁ, Urso S, González JM, Santana L, Sadaba R, Juarez P, et al. Levosimendan versus placebo in cardiac surgery: A systematic review and meta-analysis. Interact Cardiovasc Thorac Surg 2018;27:677-685. doi:10.1093/icvts/ivy133
Feng F, Chen Y, Li M, Yuan J-J, Chang X-N, Dong C-M. Levosimendan does not reduce the mortality of critically ill adult patients with sepsis and septic shock: A meta-analysis. Chin Med J (Engl) 2019;132:1212-1217. doi:10.1097/CM9.0000000000000197
Bhattacharjee S, Soni KD, Maitra S, Baidya DK. Levosimendan does not provide mortality benefit over dobutamine in adult patients with septic shock: A meta-analysis of randomized controlled trials. J Clin Anesth 2017;39:67-72. doi:10.1016/j.jclinane.2017.03.011
Maack C, Eschenhagen T, Hamdani N, Heinzel FR, Lyon AR, Manstein DJ, et al. Treatments targeting inotropy. Eur Heart J 2019;40:3626-3644. doi:10.1093/eurheartj/ehy600
Gong B, Li Z, Yat Wong PC. Levosimendan treatment for heart failure: A systematic review and meta-analysis. J Cardiothorac Vasc Anesth 2015;29:1415-1425. doi:10.1053/j.jvca.2015.03.023